Supplementary materials for
An estimate of the COVID-19 infection fatality rate in Brazil based on a seroprevalence survey

Valerio Marra[1,*] and Miguel Quartin[2,†]

[1] *Núcleo de Astrofísica e Cosmologia & Departamento de Física, Universidade Federal do Espírito Santo, Vitória, ES, Brazil*

[2] *Instituto de Física & Observatório do Valongo, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil*

CONTENTS

A. Antibody prevalence 1
B. Infection fatality rate 2
C. Error estimation 4
D. IFR for the three EPICOVID19-BR rounds 4
E. Full numerical results 5

References 5

A. Antibody prevalence

The antibody presence in the population p_a was directly assessed via the EPICOVID19-BR serological survey, which adopted the One Step COVID-19 Test from Wondfo. The test was subjected to analysis of its specificity and sensitivity by different groups including the manufacturer. Specificity and sensitivity are in turn related directly to the false positive rate (FPR) and false negative rate (FNR), respectively. The EPICOVID19-BR team consolidated different analyses of this test and arrived at a FPR = 1.0% (95% CI: 0.3–2.2%) and FNR = 15.2% (95% CI: 12.2–18.6%).[1]

If both FPR and FNR were zero, each test outcome would be drawn from a simple Binomial distribution with probability p_a. Therefore p_a would be distributed according to the conjugate-prior distribution, which for $n_{\rm tot}$ tests with $n_{\rm yes}$ positive detections, would be a Beta distribution $\mathcal{B}[\alpha,\beta](p_a)$ with $\alpha = n_{\rm yes}+1$ and $\beta = n_{\rm tot} - n_{\rm yes} + 1$. A non-zero FPR and FNR can be taken into account with a simple change of variables $p_a^{\rm obs} \to p_a^{\rm true}(1-{\rm FNR}-{\rm FPR})+{\rm FPR}$. The distribution for $p_a^{\rm true}$ can then be computed numerically to arbitrary precision, but it can also be approximated to great accuracy by a Pearson type I distribution, sometimes referred to as the 4-parameter Beta distribution, which, in our case, can be simply thought of as a displaced Beta distribution:

$$\mathcal{B}[\alpha,\beta](p_a + p_{\rm min})\,, \tag{1}$$

with $p_{\rm min} = {\rm FPR}/(1-{\rm FNR}-{\rm FPR})$ is the displacement, $\alpha = n_{\rm yes}+1$ and $\beta = n_{\rm tot}(1-{\rm FNR}-{\rm FPR})-{\rm n_{yes}}+1$. Since this mathematically allows $p_a < 0$, it must be multiplied by a uniform (or top-hat) prior enforcing $p_a \geq 0$, to wit $\mathcal{U}[0,1](p_a)$.

In order to combine the prevalence results in different cities and get results for a given state or for the whole country we proceed as follow. The combined prevalence is given by:

$$p_a^{\rm combined} = \frac{N_a}{\rm TotPop} = \frac{\sum_{{\rm city}\ i} p_{a,i}{\rm pop}_i}{\rm TotPop} = \sum_{{\rm city}\ i} p_{a,i}{\rm fpop}_i. \tag{2}$$

In the above, N_a is the number of people with antibodies in the combination of N cities, TotPop is the total combined population, $p_{a,i}$ and ${\rm pop_i}$ is the prevalence and population in city i, respectively, and ${\rm fpop}_i$ is the fraction of the total population considered in city i. This means that the distribution for $p_a^{\rm combined}$ is technically computed as a transformation of many variables $p_{a,1},\ldots,p_{a,N}$ into one variable $p_a^{\rm combined}$. This leads to the following challenging N-dimensional integral for the state s:

$$\mathcal{L}(p_{a,s}) = \mathcal{N}\int {\rm d}^N p_{a,j}\,\delta\Big[p_{a,s} - \sum_{{\rm city}\ j} p_{a,j}{\rm fpop}_j\Big]\prod_{{\rm city}\ i}\mathcal{L}_i(p_{a,i}), \tag{3}$$

where δ is the Dirac delta function and $\mathcal{N}$ a normalization constant. We have computed such integral for all states in which $N \leq 4$ and found out that this exact integral can be accurately approximated once again by a displaced Beta distribution.

The displacement is exactly as above since it comes, after all, from the FPR and FNR, which is assumed to be the same in all cities as the same test was employed. Since both displacements are equal, we start by ignoring it and compute the variables α and β in order to ensure that the combined distribution has the correct mean μ and variance V. These first 2 moments of the distribution define both parameters univocally:

$$\alpha = \frac{\mu}{V}\big(-V+\mu-\mu^2\big)\,, \quad \beta = \frac{1-\mu}{V}\big(-V+\mu-\mu^2\big)\,. \tag{4}$$

The combined μ and V in turn are easily obtained using Eqs. (2) and (4) and the properties of the mean and variance of a sum of independent random variables. To wit, if μ_i and V_i are the mean and variance of city i, we get:

$$\mu = \sum_{{\rm city}\ i}\mu_i\,{\rm fpop}_i\,, \quad V = \sum_{{\rm city}\ i} V_i\,{\rm fpop}_i^2\,. \tag{5}$$

---

* Contributed equally
† Contributed equally; Corresponding author: mquartin@if.ufrj.br

Note that since, once again, we must include the displacement and the prior $\mathcal{U}[0,1](p_a^{\rm combined})$, the above values of μ and V are for the corresponding non-displaced Beta distribution only. The full posterior for $p_a^{\rm combined}$, including the displaced and prior, will have slightly different mean and variance. The displacement leaves the variance unchanged but reduces the mean by $p_{\rm min}$. The inclusion of the prior, which removes the negative tail of the distribution, raises the mean while lowering the variance. So in order to improve the approximation in the cases where the prior affects the final distribution (this is the case for those states with few positive results, effectively irrelevant for the whole country analysis), we iterate the process one more time and adjust μ and V slightly to ensure the final distribution has approximately the correct mean and variance. We found empirically that the following adjustment works well: $\mu \to \mu\lambda^{-3/2}$ and $V \to V\lambda$, where

$$\lambda = \int_{p_{\rm min}}^{1} \mathcal{B}[\alpha,\beta](p)\mathrm{d}p\,, \tag{6}$$

is the area under the truncated Beta distribution. The resulting approximation is very good, and in particular it leads to medians (95% confidence interval widths) which differ on average from the exact result by a relative amount of just $\simeq 1\%$ ($\simeq 3\%$). Moreover, there are no severe outlier cases for this approximation, and for the whole range of states and rounds the largest discrepancy of medians was 7%. Figure 1 shows the excellent performance of the Beta distribution approximation.



Figure 1. *Top*: Beta distribution approximation of Eq. (1) for a single city, assuming 5 positive results out of 250 tests and the FNR and FPR discussed in the text. The exact numerical distribution is the solid line in orange; the Beta approximation is the dashed line in black. There is no discernible difference. *Bottom*: Beta distribution approximation of Eqs. (4) and (5) for the states AL and PE in Round 1. The exact numerical distribution is the solid line in orange; the Beta approximation is the dashed line in black. There is only a small difference in the cases where the maximum likelihood is very small ($p_a < 0.015$), otherwise the approximation is indistinguishable.

B. Infection fatality rate

In order to estimate the IFR we need to relate the cumulative number $n_+(t)$ of COVID-19 cases to the cumulative number $n_a(t)$ of patients with SARS-CoV-2 antibodies and the cumulative number $n_d(t)$ of non-survivors. To this end we need to estimate the average time τ_{ca} from contagion to antibody presence and the average time τ_{cd} from contagion to death, and then compute the time-delay between antibodies and death $\tau_{ad} \simeq \tau_{sd} - \tau_{sa} \simeq \tau_{cd} - \tau_{ca}$.

We obtain τ_{ca} from the mean of the convolution $\mathrm{d}f_{ca}/\mathrm{d}t$ of the distributions of the time from contagion to symptoms onset $\mathrm{d}f_{cs}/\mathrm{d}t$ and from symptoms onset to antiviral immunoglobulin G (IgG) and/or M (IgM) presence $\mathrm{d}f_{sa}/\mathrm{d}t$:

$$\frac{\mathrm{d}f_{ca}(t)}{\mathrm{d}t} = \int_0^t \mathrm{d}\bar{t}\,\frac{\mathrm{d}f_{sa}(\bar{t})}{\mathrm{d}\bar{t}}\,\frac{\mathrm{d}f_{cs}}{\mathrm{d}t}(t-\bar{t})\,, \tag{7}$$

$$f_{ca}(t) = \int_0^t \mathrm{d}\bar{t}\,\frac{\mathrm{d}f_{ca}(\bar{t})}{\mathrm{d}\bar{t}} \simeq H(t-\tau_{ca})\,, \tag{8}$$

where in the last equation we used the instantaneous approximation according to which $\mathrm{d}f_{ca}/\mathrm{d}t \simeq \delta(t-\tau_{ca})$ is a Dirac delta function so that f_{ca} is modeled as a Heaviside step function. The distribution $\mathrm{d}f_{sa}/\mathrm{d}t$ is modeled empirically,[2] while $\mathrm{d}f_{cs}/\mathrm{d}t$ according to a lognormal template.[3] The means τ_{ca}, τ_{cs} and τ_{sa} relative to $\mathrm{d}f_{ca}/\mathrm{d}t$, $\mathrm{d}f_{cs}/\mathrm{d}t$ and $\mathrm{d}f_{sa}/\mathrm{d}t$ are reported in Table II of the main text. Note that $\tau_{ca} \simeq \tau_{cs} + \tau_{sa}$. The functions $f_{ca}(t)$ and $H(t-\tau_{ca})$ are shown in Figure 2. τ_{sd} is in agreement with the average time from symptoms onset to death relative to other countries.[4,5]

Similarly, we obtain τ_{cd} from the mean of the convolution $\mathrm{d}f_{cd}/\mathrm{d}t$ of the distributions of the time from contagion to symptoms onset $\mathrm{d}f_{cs}/\mathrm{d}t$ and from symptoms onset to death $\mathrm{d}f_{sd}/\mathrm{d}t$:

$$\frac{\mathrm{d}f_{cd}(t)}{\mathrm{d}t} = \int_0^t \mathrm{d}\bar{t}\,\frac{\mathrm{d}f_{sd}(\bar{t})}{\mathrm{d}\bar{t}}\,\frac{\mathrm{d}f_{cs}}{\mathrm{d}t}(t-\bar{t})\,, \tag{9}$$

$$f_{cd}(t) = \int_0^t \mathrm{d}\bar{t}\,\frac{\mathrm{d}f_{cd}(\bar{t})}{\mathrm{d}\bar{t}} \simeq H(t-\tau_{cd})\,. \tag{10}$$

The distribution $\mathrm{d}f_{sd}/\mathrm{d}t$ is modeled empirically using the data from the SIVEP-Gripe dataset at the Brazilian and state levels as described below. Note that $\tau_{cd} \simeq \tau_{cs} + \tau_{sd}$.



Figure 2. Cumulative probability distribution of IgG and/or IgM presence as a function of days after contagion.

The data from SIVEP-Gripe is biased towards cases with severe symptoms. Indeed, there is a significant number of cases that are hospitalized when symptoms are notified (see Figure 3, top panel). In order to take this into account we introduce a delay parameter τ_Δ (see Table II of the main text) which models the time that a patient takes on average to go from symptoms onset to severe symptoms:

$$\frac{\mathrm{d}f_{sd}}{\mathrm{d}t}(t) = \int_0^t \mathrm{d}\bar{t}\, \frac{\mathrm{d}f_{sd}^{\mathrm{sivep}}(\bar{t})}{\mathrm{d}\bar{t}}\, \frac{\mathrm{d}f_\Delta}{\mathrm{d}t}(t-\bar{t}) \simeq \frac{\mathrm{d}f_{sd}^{\mathrm{sivep}}}{\mathrm{d}t}(t-\tau_\Delta), \tag{11}$$

where we again used the instantaneous approximation for the distribution $\mathrm{d}f_\Delta/\mathrm{d}t$ and τ_Δ is its mean. We estimate $\tau_\Delta = 2$ days.[6] This means that $\tau_{sd} = \tau_{sd}^{\mathrm{sivep}} + \tau_\Delta$. The distribution $\mathrm{d}f_{sd}^{\mathrm{sivep}}/\mathrm{d}t$ at the Brazilian level is shown in Figure 3 (bottom panel). In the computation of the IFR we will adopt the median of $\mathrm{d}f_{sd}^{\mathrm{sivep}}/\mathrm{d}t$ as a robust measure of $\tau_{sd}^{\mathrm{sivep}}$.

We can now relate the cumulative number $n_+(t)$ of COVID-19 cases to the cumulative number $n_a(t)$ of patients with SARS-CoV-2 antibodies and the cumulative number $n_d(t)$ of non-survivors:

$$n_a(t) = \int_{t_0}^t \mathrm{d}\bar{t}\, \frac{\mathrm{d}n_+(\bar{t})}{\mathrm{d}\bar{t}} f_{ca}(t-\bar{t}) \simeq n_+(t-\tau_{ca})\,, \tag{12}$$

$$n_d(t) = \mathrm{IFR} \int_{t_0}^t \mathrm{d}\bar{t}\, \frac{\mathrm{d}n_+(\bar{t})}{\mathrm{d}\bar{t}} f_{cd}(t-\bar{t}) \simeq \mathrm{IFR}\, n_+(t-\tau_{cd}), \tag{13}$$

where we assumed that IFR is constant. The number of fatalities is obtained via the public Painel Coronavírus dataset. Figure 4 shows the new deaths $\mathrm{d}n_d/\mathrm{d}t$ for the 133 cities that entered the EPICOVID19-BR survey. From $\mathrm{d}n_d/\mathrm{d}t$ we can compute the cumulative number of deaths $n_d(t)$.

We can now use the previous two equations to compute



Figure 3. *Top*: distribution of times from symptoms onset to hospitalization. *Middle*: distribution of times from hospitalization to death. *Bottom*: distribution of times from symptoms onset to death. The means are given in the Table II of the main text. From SIVEP-Gripe data of June 16, 2020.

the IFR:

$$\mathrm{IFR} = \frac{n_d(t)}{n_+(t-\tau_{cd})} = \frac{n_d(\bar{t}+\tau_{cd}-\tau_{ca})}{n_a(\bar{t})} \simeq \frac{n_d(\bar{t}+\tau_{sd}-\tau_{sa})}{n_a(\bar{t})} = \frac{p_d(\bar{t}+\tau_{sd}-\tau_{sa})}{p_a(\bar{t})}, \tag{14}$$

where $\bar{t}$ is the time relative to the measurement of n_a and in the last equation we divided numerator and denominator by the number n_{pop} of inhabitants according to the 2019 IBGE population values, $p_d = n_d/n_{\mathrm{pop}}$. As explained earlier, we estimate p_a using EPICOVID19-BR data and p_d using the Painel Coronavírus data shown in Figure 4. We smooth the Painel Coronavírus data according to a 7-day moving average that assigns to the time t_0 the average value of deaths in the internal $[t_0, t_0 + 6 \text{ days}]$. Indeed, for many reasons, but mostly because of weekends, deaths that happen at the time t_0 are reported at a later time that we estimate according



Figure 4. New deaths by COVID-19 for the 133 cities that entered the EPICOVID19-BR survey—the windows mark its three phases. From Painel Coronavírus data of July 17, 2020.

to a flat distribution in the above mentioned interval.

We estimate the IFR at the state and Brazilian level. This means that in Eq. (14) n_d, τ_{sd} and $n_{\rm pop}$ are calculated accordingly.

C. Error estimation

We estimate the error on p_d by propagating all sources of statistical errors, which are the uncertainty on f_a and the uncertainty on f_d due to the uncertainty on τ_{sd}. We estimate the error on τ_{sd} by adding in quadrature the uncertainty on τ_Δ and the uncertainty on $\tau_{sd}^{\rm sivep}$. We estimate the former as $\sigma_\Delta = 1$ day and the latter via bootstrapping from the empirical distribution. Systematic uncertainties are discussed in the main text. Our results relative to f_a and IFR are given in terms of the maxima of the likelihood and highest density intervals.

For the uncertainties of the IFR, we find that the relative error on p_d to be smaller than the one in p_a by a factor between 3.5 to 5 depending on the survey round. We can therefore approximate p_d as a fixed variable in Eq. (14). We then take into account the full distribution of IFR due to the uncertainties in p_a. The distribution on the IFR is thus the one of the inverse of a truncated Beta distribution, the PDF of which can be written in closed form as:

$$\frac{p_d\,\Gamma(\alpha+\beta)\left(\frac{p_d}{x}+p_{\rm min}\right)^{\alpha}\left(1-p_{\rm min}-\frac{p_d}{x}\right)^{\beta}}{\Gamma(\alpha)\Gamma(\beta)(p_d+p_{\rm min}x)\left[p_d-(1-p_{\rm min})x\right]\left(I_{p_{\rm min}}[\alpha,\beta]-1\right)} \tag{15}$$

for $x > p_d/(1+p_{\rm min})$ and zero otherwise. Here, x is the free variable, in our case the IFR, I is the regularized incomplete Beta function, and Γ is the gamma function.

As the error budget is driven by the uncertainty on f_a and the determinations of f_a during the three rounds are statistically independent, we can combine the rounds by simply multiplying the likelihoods. This combination allows for a more precise estimate of the average IFR over all rounds. Clearly, this ignores possible changes of the IFR during the course of the 5 weeks between rounds 1 and 3, and in fact, our results do point out to an increase of the IFR in round 3 as compared to the previous rounds.



Figure 5. Separate IFR estimates for each of the 3 rounds for each state (maximum likelihood and 95% CI). The lower statistics leads to larger uncertainties.

D. IFR for the three EPICOVID19-BR rounds

Brazil is divided geopolitically into 5 macroregions, the 27 states of which are:

- North: Acre (AC), Amapá (AP), Amazonas (AM), Pará (PA), Rondônia (RO), Roraima (RR), Tocantins (TO);
- Northeast: Alagoas (AL), Bahia (BA), Ceará (CE), Maranhão (MA), Paraíba (PB), Pernambuco (PE), Piauí (PI), Rio Grande do Norte (RN), Sergipe (SE);
- Central-West: Distrito Federal (DF), Goiás (GO), Mato Grosso (MT), Mato Grosso do Sul (MS);
- Southeast: Espírito Santo (ES), Minas Gerais (MG), Rio de Janeiro (RJ), São Paulo (SP);
- South: Paraná (PR), Rio Grande do Sul (RS), Santa Catarina (SC).

The acronyms for these 27 states are used in Figures 2 and 4 of the main text.

Figure 5 shows the IFR estimates for the three EPICOVID19-BR rounds for each state. In most states we note a general increase in IFR on Round 2 and 3, and specially in the latter. In Roraima (RR) we also note a statistically significant discrepant IFR result in round 2. In Piauí (PI) we see a similar but opposite behaviour, but the larger uncertainties make it less significant.

E. Full numerical results

State	p_a R1 (%)	p_a R2 (%)	p_a R3 (%)	p_d R1 (‰)	p_d R2 (‰)	p_d R3 (‰)	IFR R1 (%)	IFR R2 (%)	IFR R3 (%)	IFR all rounds (%)
AC	4.1 (6.9–95.)	5.9 (8.6–95.)	5.1 (7.7–95.)	0.18 (0.12–0.25)	0.42 (0.36–0.48)	0.59 (0.54–0.64)	0.39 (0.22–0.87)	0.66 (0.44–1.1)	1.1 (0.69–1.9)	0.77 (0.59–1.1)
AL	0.85 (2.3–95.)	9.7 (14.–95.)	13. (18.–95.)	0.18 (0.17–0.2)	0.38 (0.37–0.4)	0.51 (0.5–0.53)	1.2 (0.37–17.)	0.37 (0.26–0.57)	0.37 (0.28–0.52)	0.43 (0.34–0.55)
AM	12. (16.–95.)	14. (18.–95.)	7.7 (11.–95.)	0.6 (0.58–0.62)	0.75 (0.74–0.76)	0.83 (0.82–0.84)	0.49 (0.35–0.73)	0.53 (0.39–0.75)	1. (0.67–1.7)	0.64 (0.53–0.8)
AP	8.8 (13.–95.)	14. (19.–95.)	13. (18.–95.)	0.22 (0.18–0.25)	0.39 (0.36–0.42)	0.52 (0.49–0.54)	0.23 (0.15–0.38)	0.27 (0.2–0.39)	0.37 (0.27–0.54)	0.3 (0.25–0.37)
BA	0.93 (1.8–95.)	4.1 (6.6–95.)	2.4 (4.2–95.)	0.088 (0.078–0.098)	0.18 (0.17–0.19)	0.29 (0.28–0.31)	0.73 (0.34–2.8)	0.39 (0.23–0.79)	1. (0.57–2.5)	0.72 (0.51–1.1)
CE	6.9 (10.–95.)	13. (17.–95.)	18. (22.–95.)	0.6 (0.56–0.65)	0.98 (0.96–1.)	1.1 (1.1–1.1)	0.81 (0.52–1.4)	0.72 (0.54–1.)	0.62 (0.49–0.81)	0.68 (0.58–0.82)
DF	0.39 (1.3–95.)	0.63 (2.–95.)	0.63 (2.–95.)	0.05 (0.045–0.055)	0.12 (0.11–0.13)	0.22 (0.21–0.24)	0.51 (0.1–20.)	0.82 (0.19–23.)	1.6 (0.37–44.)	1. (0.49–2.8)
ES	1.2 (2.7–95.)	1.6 (2.8–95.)	2.7 (4.3–95.)	0.13 (0.12–0.14)	0.3 (0.28–0.32)	0.49 (0.47–0.51)	0.68 (0.26–5.)	1.6 (0.8–4.6)	1.6 (0.97–3.1)	1.5 (1.–2.2)
GO	0.41 (1.1–95.)	0.44 (1.1–95.)	1.1 (2.2–95.)	0.026 (0.024–0.027)	0.05 (0.046–0.054)	0.12 (0.1–0.13)	0.34 (0.12–5.1)	0.67 (0.24–8.1)	0.76 (0.31–4.6)	0.63 (0.39–1.2)
MA	1.4 (3.5–95.)	6.8 (9.4–95.)	7.2 (9.6–95.)	0.35 (0.34–0.36)	0.5 (0.48–0.52)	0.65 (0.63–0.66)	1.5 (0.5–15.)	0.7 (0.5–1.1)	0.87 (0.64–1.3)	0.84 (0.67–1.1)
MG	0.99 (1.8–95.)	0.47 (0.89–95.)	0.65 (1.3–95.)	0.02 (0.019–0.021)	0.037 (0.034–0.04)	0.079 (0.073–0.085)	0.16 (0.08–0.52)	0.6 (0.29–2.5)	0.92 (0.44–3.9)	0.64 (0.43–1.1)
MS	0.71 (2.2–95.)	0.45 (1.2–95.)	0.59 (1.4–95.)	0.0065 (0.0056–0.0074)	0.014 (0.0097–0.018)	0.052 (0.038–0.067)	0.04 (0.01–0.92)	0.16 (0.05–2.8)	0.54 (0.19–6.)	0.33 (0.19–0.72)
MT	5.3 (12.–95.)	0.94 (1.9–95.)	0.65 (1.4–95.)	0.019 (0.014–0.024)	0.1 (0.07–0.13)	0.26 (0.19–0.33)	0.02 (0.01–0.14)	0.77 (0.33–4.3)	2.7 (1.1–19.)	1.6 (0.99–3.2)
PA	12. (15.–95.)	13. (16.–95.)	6.4 (8.4–95.)	0.59 (0.56–0.63)	0.88 (0.86–0.89)	0.99 (0.98–1.)	0.48 (0.38–0.63)	0.66 (0.53–0.85)	1.5 (1.1–2.1)	0.84 (0.72–0.98)
PB	1.7 (3.7–95.)	4.9 (7.2–95.)	1.8 (3.3–95.)	0.1 (0.091–0.11)	0.24 (0.23–0.25)	0.38 (0.36–0.41)	0.4 (0.16–2.3)	0.45 (0.3–0.75)	1.7 (0.85–5.4)	0.83 (0.6–1.2)
PE	2.6 (4.7–95.)	2. (3.9–95.)	0.78 (1.9–95.)	0.39 (0.36–0.42)	0.65 (0.62–0.67)	0.82 (0.81–0.84)	1.2 (0.62–3.5)	2.5 (1.1–9.5)	6.4 (2.3–67.)	3.3 (2.1–5.8)
PI	3.5 (7.4–95.)	1.4 (2.7–95.)	8.2 (11.–95.)	0.072 (0.062–0.082)	0.22 (0.2–0.24)	0.42 (0.4–0.45)	0.15 (0.06–0.68)	1.3 (0.6–4.5)	0.49 (0.35–0.73)	0.63 (0.47–0.87)
PR	0.55 (1.1–95.)	0.74 (1.7–95.)	0.82 (1.5–95.)	0.021 (0.019–0.023)	0.047 (0.043–0.052)	0.089 (0.084–0.095)	0.27 (0.12–1.6)	0.4 (0.15–3.7)	0.88 (0.45–2.8)	0.63 (0.41–1.1)
RJ	1.8 (3.7–95.)	5.7 (8.9–95.)	8.1 (12.–95.)	0.4 (0.37–0.43)	0.67 (0.64–0.69)	0.87 (0.85–0.89)	1.6 (0.65–8.5)	1.1 (0.65–2.)	1. (0.67–1.6)	1.1 (0.83–1.5)
RN	2.1 (4.2–95.)	3.3 (5.7–95.)	5. (7.6–95.)	0.11 (0.096–0.12)	0.25 (0.23–0.27)	0.52 (0.49–0.54)	0.39 (0.18–1.5)	0.64 (0.36–1.5)	0.94 (0.6–1.7)	0.76 (0.55–1.1)
RO	0.67 (2.–95.)	2.1 (4.3–95.)	5.5 (8.6–95.)	0.16 (0.15–0.17)	0.4 (0.37–0.43)	0.59 (0.58–0.6)	1.2 (0.33–23.)	1.4 (0.63–5.7)	0.97 (0.6–1.8)	1.1 (0.77–1.8)
RR	3.7 (6.6–95.)	24. (29.–95.)	21. (26.–95.)	0.19 (0.16–0.22)	0.39 (0.35–0.43)	0.61 (0.52–0.71)	0.42 (0.22–1.1)	0.16 (0.13–0.21)	0.29 (0.23–0.38)	0.24 (0.2–0.29)
RS	0.43 (0.87–95.)	0.46 (0.93–95.)	0.47 (0.93–95.)	0.023 (0.022–0.023)	0.036 (0.034–0.038)	0.062 (0.058–0.067)	0.36 (0.16–2.3)	0.55 (0.24–3.4)	0.95 (0.43–5.1)	0.68 (0.44–1.2)
SC	0.51 (0.96–95.)	0.52 (0.98–95.)	0.61 (1.1–95.)	0.022 (0.021–0.023)	0.03 (0.027–0.034)	0.052 (0.046–0.057)	0.34 (0.17–1.3)	0.45 (0.23–1.7)	0.67 (0.34–2.4)	0.51 (0.35–0.83)
SE	0.46 (1.4–95.)	0.67 (1.8–95.)	2.9 (5.5–95.)	0.061 (0.04–0.082)	0.19 (0.15–0.23)	0.39 (0.33–0.46)	0.64 (0.18–14.)	1.5 (0.47–25.)	1.1 (0.53–3.4)	1.1 (0.68–2.1)
SP	2.2 (4.3–95.)	1.3 (2.8–95.)	0.83 (1.9–95.)	0.24 (0.23–0.26)	0.37 (0.35–0.38)	0.49 (0.47–0.5)	0.86 (0.39–3.1)	1.9 (0.76–12.)	3.6 (1.3–35.)	2.2 (1.4–4.)
TO	0.39 (0.94–95.)	0.64 (1.4–95.)	1.3 (2.3–95.)	0.045 (0.037–0.053)	0.095 (0.079–0.11)	0.15 (0.14–0.17)	0.68 (0.25–8.)	0.96 (0.37–8.)	0.97 (0.5–2.9)	0.9 (0.59–1.6)

Table I. Maxima of the likelihood and 95% CI. p_d is given in parts per thousands.

[1] M. F. Silveira, A. J. Barros, B. Horta L, *et al.*, "Population-based surveys of antibodies against sars-cov-2 in southern brazil," *Nature Medicine* (2020) 1–4.

[2] Q.-X. Long, B.-Z. Liu, H.-J. Deng, *et al.*, "Antibody responses to SARS-CoV-2 in patients with COVID-19," *Nature Medicine* **26** no. 6, (2020) 845–848.

[3] S. A. Lauer, K. H. Grantz, Q. Bi, *et al.*, "The incubation period of coronavirus disease 2019 (covid-19) from publicly reported confirmed cases: Estimation and application," *Annals of Internal Medicine* **172** no. 9, (2020) 577–582.

[4] P. H. P. Cintra and F. Fontinele Nunes, "Estimative of real number of infections by covid-19 on brazil and possible scenarios," *medRxiv* (2020) .

[5] Imperial College COVID-19 response team, "Short-term forecasts of COVID-19 deaths in multiple countries," 2020. https://mrc-ide.github.io/covid19-short-term-forecasts. (accessed June 26, 2020).

[6] K. Gaythorpe, N. Imai, G. Cuomo-Dannenburg, *et al.*, "Report 8: Symptom progression of COVID-19," *Imperial College London* (2020) 1–11.